Association of MUC19 Mutation With Clinical Benefits of Anti-PD-1 Inhibitors in Non-small Cell Lung Cancer

Although anti-PD-1 inhibitors exhibit impressive clinical results in non-small cell lung cancer (NSCLC) cases, a substantial percentage of patients do not respond to this treatment. Moreover, the current recommended biomarkers are not perfect. Therefore, it is essential to discover novel molecular d...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Li, Huang, Litang, Xu, Qiuli, Lv, Yanling, Wang, Zimu, Zhan, Ping, Han, Hedong, Shao, Yang, Lin, Dang, Lv, Tangfeng, Song, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019943/
https://www.ncbi.nlm.nih.gov/pubmed/33828970
http://dx.doi.org/10.3389/fonc.2021.596542

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019943/
https://www.ncbi.nlm.nih.gov/pubmed/33828970
http://dx.doi.org/10.3389/fonc.2021.596542

Ejemplares similares